June 24, 2015 / 11:44 AM / 2 years ago

BUZZ-Transition Therapeutics Inc: Alzheimer's drug fails study

** Drug developer’s shares down 20 pct at $7.30 premarket

** Says mid-stage study of its experimental neuropshychiatric drug, ELND005, did not meet main goal of significant reduction in agitation and aggression

** Study was testing patients with mild to severe Alzheimer’s disease

** Says external advisory panel will be consulted to decide future of drug

** Up to Tuesday’s close, stock had risen 27 pct in 12 months

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below